Avenue Therapeutics Inc (NASDAQ:ATXI) has received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Brokers have set a one year consensus price objective of $12.67 for the company and are anticipating that the company will post ($0.35) EPS for the current quarter, according to Zacks. Zacks has also given Avenue Therapeutics an industry rank of 87 out of 255 based on the ratings given to related companies.
Several research firms have recently weighed in on ATXI. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Avenue Therapeutics in a research report on Wednesday, August 15th. Oppenheimer set a $8.00 target price on shares of Avenue Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 15th.
NASDAQ ATXI traded up $0.32 during mid-day trading on Monday, reaching $3.69. 919,164 shares of the stock were exchanged, compared to its average volume of 38,916. Avenue Therapeutics has a 1-year low of $2.08 and a 1-year high of $5.90. The firm has a market cap of $29.76 million, a P/E ratio of -2.08 and a beta of -1.17.
Avenue Therapeutics (NASDAQ:ATXI) last posted its earnings results on Tuesday, August 14th. The company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.23. Analysts anticipate that Avenue Therapeutics will post -2.31 EPS for the current fiscal year.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
Featured Story: What is intrinsic value?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.